NCT07199452

A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

An Open-Label Clinical Study to Evaluate the Effects of Multiple Oral Doses of Rifabutin on the Single-Dose Pharmacokinetics of MK-4646 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB). Researchers want to learn about MK-4646 when taken at the same time as Rifabutin. They want to: Measure a person's blood to find out if the amount of MK-4646 in the blood is the same when MK-4646 is taken alone or with Rifabutin Learn about the safety of MK-4646 when taken alone or with Rifabutin and if people tolerate it

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MK-4646	Oral Capsule
DRUG	Rifabutin	Oral Capsule

Timeline

• Start date: 2025-10-28
• Primary completion: 2025-12-27
• Completion: 2026-01-07
• First posted: 2025-09-30
• Last updated: 2026-01-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study